Calidi Biotherapeutics (CLDI) Stock Statistics & Valuation Metrics

Calidi Biotherapeutics has a market cap or net worth of $14.78M. The enterprise value is $21.65M.

Calidi Biotherapeutics has 33.59M shares outstanding. The number of shares has decreased by -2.65% in one year.

Calidi Biotherapeutics’s return on equity (ROE) is 3.55 and return on invested capital (ROIC) is -1696.37%.

The current PE Ratio of Calidi Biotherapeutics is -8.73. Calidi Biotherapeutics’s PEG ratio is 0.09.

In the last 12 months, Calidi Biotherapeutics had revenue of $0.00 and earned -$17.07M in profits. Earnings per share was -$8.76.

In the last 12 months, operating cash flow was -$31.01M and capital expenditures -$896.00K, giving a free cash flow of -$31.90M billion.

Calidi Biotherapeutics pays an annual dividend of , resulting in a dividend yield of

Calidi Biotherapeutics upcoming earnings date is May 20, 2025, After Close.

Calidi Biotherapeutics as a current ratio of 0.42, with Debt / Equity ratio of -0.88

In the past 12 months, Calidi Biotherapeutics has paid $89.95K in taxes.

Calidi Biotherapeutics EV to EBITDA ratio is -9.43, with an EV/FCF ratio of -9.44.

Calidi Biotherapeutics has $1.24M in cash and marketable securities with $11.71M in debt, giving a net cash position of $10.47M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Calidi Biotherapeutics is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy